BioSpace News Archive

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Munich/ Martinsried Medigene AG, a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announces that Medigene’s researchers presented clinical immune monitoring data obtained during the first year of treatment from the ongoing Phase I/II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia at the 61st ASH Annual Meeting.

SureClinical, a global provider of innovative cloud solutions for the health sciences market announced its new cloud-based regulatory document management solution for clinical investigator sites, SureISF.

BioGenerator-backed company is first to manufacture digital health device in St. Louis

Scientific collaboration to study the anti-inflammatory activity of gut beneficial bacteria, more specifically Christensenella for which LNC Therapeutics holds an exclusive worldwide license

New findings from the Phase III KEYNOTE-042 Study show improvements in overall survival, progression-free survival and overall response rate in patients treated with Keytruda as a monotherapy.

The FDA advisory committee met and voted 11 to 2 against recommending approval of Brinavess, citing safety concerns. The FDA is not required to follow the recommendations of its adcoms, but typically does.

With $6.5 million in seed funding, Aspen Neuroscience, Inc. launched today with a goal of developing the first autologous cell therapies for Parkinson’s disease.

Study will evaluate the safety and efficacy of the combination of iTeos’ EOS100850 and Merck’s KEYTRUDA® (pembrolizumab)

Lead investigators from US and French Phase Ib/II clinical trials of APR-246 and Azacitidine in patients with TP53 mutant MDS and AML, presented positive data on Monday at the 2019 ASH Annual Meeting.